Ratio Therapeutics

Boston-based developer of radiopharmaceuticals for cancer treatment; raised $70 million in Series C from Duquesne Family Office, Bristol Myers Squibb, and Catalio Capital Management. Distinct from the unrelated "Rise Therapeutics, LLC."